Lysogene partners with Weizmann Institute

By The Science Advisory Board staff writers

July 1, 2020 -- Lysogene has inked a research agreement with Yeda Research and Development, the commercial arm of the Weizmann Institute of Science, for novel gene therapy.

Through the collaboration, Lysogene and Anthony Futerman, PhD, of the Weizmann Institute will work to develop a novel adeno-associated virus (AAV) gene therapy approach for neuronopathic Gaucher disease, Parkinson's disease, and other diseases associated with mutations of the GBA1 gene.

Under the terms of the agreement, Lysogene will provide expertise in AAV vector design and production, while Futerman's lab will provide glucocerebrosidase variants with enhanced biological properties and conduct proof-of-concept biological studies. Subsequently, Lysogene will have the option to license the program.

Novasep, Lysogene partner for gene therapy
Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector-based...

Copyright © 2020

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter